From Candidate to Clinic: Strategies to Accelerate Your Molecule’s Development Path
The development of orally administered small molecules is more challenging as an many have poor aqueous solubility and bioavailability.
The development of orally administered small molecules is more challenging as an many have poor aqueous solubility and bioavailability.
Summary: Characterize lead molecules and develop the best pathway to bring them to Phase I studies and beyond.
Summary: Thousands of drug candidates are abandoned annually due to solubility and bioavailability issues, but advanced formulation technologies can profoundly impact how a drug compound…
This webinar focuses on the key considerations for transitioning small molecules from preclinical through clinical development.
Summary: Recorded at Manufacturing Chemist Live 2020, this presentation discusses some of the key issues to consider when planning for the scale-up of a small molecule development program.
Summary: Dramatically shifting the attention of the industry, Covid-19 forced orphan developers to re-examine their go-to-market strategies.